Table of Contents 3
List of Tables 5
List of Figures 5
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 11
Venture Financing 12
Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 12
Partnerships 13
ContraVir Pharma Enters into Agreement with Li Ka Shing Institute of Virology 13
Center Point Clinical Services Enters into Agreement with ContraVir Pharma 14
Licensing Agreements 15
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 15
Equity Offering 17
ContraVir Pharma to Raise USD10.8 Million Rights Offering of Shares 17
ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 18
ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 19
ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 20
ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 22
ContraVir Pharma Spin Off from Synergy Pharma 23
ContraVir Pharma Completes Private Placement Of Securities For US$3 Million 24
Debt Offering 25
ContraVir Pharma Raises USD3.3 Million in Private Placement of 10% Notes Due 2019 25
Acquisition 26
ContraVir Pharma Acquires Ciclofilin Pharma 26
ContraVir Pharmaceuticals Inc - Key Competitors 27
ContraVir Pharmaceuticals Inc - Key Employees 28
ContraVir Pharmaceuticals Inc - Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Corporate Communications 30
Oct 03, 2018: ContraVir Pharmaceuticals names Robert Foster as acting Chief Executive Officer 30
Jun 20, 2018: ContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements 31
Apr 09, 2018: ContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board 32
Feb 05, 2018: Contravir Pharmaceuticals Receives Positive Nasdaq Listing Determination 33
Dec 29, 2017: ContraVir Pharmaceuticals Announces John Sullivan-Bolyai, M.D., MPH Steps Down as Chief Medical Officer 34
Product News 35
11/27/2017: ContraVir Pharmaceuticals to Make Presentation on CRV431 at HEP DART 2017 35
11/27/2017: ContraVir Pharmaceuticals to Make Presentations at HEP DART 2017 36
10/12/2017: ContraVir Pharmaceuticals to Present Poster on CMX-157 at AASLD 2017 and Participate in Search for HBV / HDV Cure Analyst Day 37
10/12/2017: ContraVir Pharmaceuticals to Present two Posters on CRV-431 at AASLD 2017 38
09/19/2017: ContraVir Pharmaceuticals Announces Participation at the Discovery on Target 2017 Conference in Boston 39
09/11/2017: ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex in the United States 40
09/06/2017: ContraVir Pharmaceuticals Announces Acceptance of Clinical Trial Application in the United Kingdom 41
05/04/2017: ContraVir to Advance Second-Generation Formulation of Tenofovir Exalidex for Treatment of Hepatitis B Virus 42
04/22/2017: Data Enhances Understanding of ContraVir's Complementary Anti-HBV Compounds Tenofovir Exalidex and CRV431 43
04/12/2018: ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress 44
04/11/2017: ContraVir to Highlight New Data on Tenofovir Exalidex at EASL The International Liver Congress 2017 in Amsterdam, The Netherlands 46
04/11/2017: ContraVir to Present Data on CRV431 at EASL The International Liver Congress 2017 in Amsterdam, The Netherlands 47
04/04/2017: ContraVir's Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg) 48
04/03/2018: ContraVir Pharmaceuticals to Present On its HBV Drug Candidate CMX-157 at the 53rd Annual International Liver Congress 49
04/03/2018: ContraVir Pharmaceuticals to Present On its HBV Drug Candidate CRV-431 at the 53rd Annual International Liver Congress 50
01/03/2017: ContraVir Awarded Grant from Canada's National Research Council to Advance CRV431 for the Treatment of Hepatitis B 51
Product Approvals 52
Feb 22, 2018: ContraVir Pharmaceuticals Announces TXL Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population 52
Feb 12, 2018: ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL Leveraging the 505(b)(2) Regulatory Pathway 53
Clinical Trials 54
Feb 06, 2018: ContraVir Pharmaceuticals Completes Renal Impairment Study with TXL 54
Oct 24, 2017: ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431 55
Oct 19, 2017: ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial with TXL 56
Aug 08, 2017: ContraVir Pharmaceuticals Selected to Present Poster on TXL at the Upcoming AASLD Meeting 2017 57
Aug 03, 2017: ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting 2017 58
Apr 20, 2017: Oral Presentation at EASL Highlights ContraVir's Tenofovir Exalidex Antiviral Activity in Hepatitis B Patients 59
Feb 14, 2017: ContraVir to Highlight Clinical Data from Ongoing Phase 2a Study of Tenofovir Exalidex for Treating Hepatitis B 60
Other Significant Developments 61
Aug 06, 2018: Contravir Pharmaceuticals provides an update to corporate objective 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraVir Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 11
Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 12
ContraVir Pharma Enters into Agreement with Li Ka Shing Institute of Virology 13
Center Point Clinical Services Enters into Agreement with ContraVir Pharma 14
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 15
ContraVir Pharma to Raise USD10.8 Million Rights Offering of Shares 17
ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 18
ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 19
ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 20
ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 22
ContraVir Pharma Spin Off from Synergy Pharma 23
ContraVir Pharma Completes Private Placement Of Securities For US$3 Million 24
ContraVir Pharma Raises USD3.3 Million in Private Placement of 10% Notes Due 2019 25
ContraVir Pharma Acquires Ciclofilin Pharma 26
ContraVir Pharmaceuticals Inc, Key Competitors 27
ContraVir Pharmaceuticals Inc, Key Employees 28
ContraVir Pharmaceuticals Inc, Other Locations 29
ContraVir Pharmaceuticals Inc, Subsidiaries 29

List of Figures
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9